1'-Methylindan-2-spiro-2'-piperazin | 51594-39-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 1'-Methylindan-2-spiro-2'-piperazin
• 英文别名: 1'-methyl-spiro[indan-2,2'-piperazine]；1'-Methylspiro[1,3-dihydroindene-2,2'-piperazine]
• CAS: 51594-39-9
• 化学式: C₁₃H₁₈N₂
• 分子量: 202.299
• InChiKey: QTHYFPFBCKZEIH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• 6-(4-Hydroxy-phenyl)-3-alkyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
  申请人：SANOFI

  公开号：US20130085128A1

  公开（公告）日：2013-04-04

  The present invention relates to pyrazolo[3,4-b]pyridine compounds of the formula I, in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are defined as indicated below. The compounds of the formula I are kinase inhibitors, and are useful for the treatment of diseases associated with diabetes and diabetic complications, such as, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy, for example. The invention furthermore relates to the use of compounds of the formula I, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I的吡唑并[3,4-b]吡啶化合物，其中R1、R2、R3、R4、R5、R6和R7如下所示。式I的化合物是激酶抑制剂，适用于治疗与糖尿病及糖尿病并发症相关的疾病，如糖尿病肾病、糖尿病神经病变和糖尿病视网膜病变等。此外，本发明还涉及式I的化合物的用途，特别是作为药物中的活性成分以及包含它们的药物组合物。
• [EN] 6-(4-HYDROXY-PHENYL)-3-ALKYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS D'AMIDE D'ACIDE 6-(4-HYDROXYPHÉNYL)-3-ALKYL-1H-PYRAZOLO[3,4-B] PYRIDINE-4-CARBOXYLIQUE UTILISÉS COMME INHIBITEURS DE KINASE
  申请人：SANOFI SA

  公开号：WO2013045413A1

  公开（公告）日：2013-04-04

  The present invention relates to pyrazolo[3,4-b]pyridine compounds of the formula (I), in which R1, R2, R3, R4, R5, R6 and R7 are defined as indicated below. The compounds of the formula (I) are protein kinase C (PKC) inhibitors, and are useful for the treatment of diseases associated with diabetes and diabetic complications, such as, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy, for example. The invention furthermore relates to the use of compounds of the formula, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式(I)的吡唑并[3,4-b]吡啶化合物，其中R1、R2、R3、R4、R5、R6和R7如下所示。式(I)的化合物是蛋白激酶C（PKC）抑制剂，并且对于治疗与糖尿病和糖尿病并发症相关的疾病，例如糖尿病肾病、糖尿病神经病和糖尿病视网膜病变等，非常有用。此外，本发明还涉及使用该式化合物，特别是作为药物中的活性成分，以及包含它们的制药组合物。
• Method for enhancing mutant enzyme activities in lysosomal storage disorders
  申请人：Mount Sinai School of Medicine

  公开号：US20020198225A1

  公开（公告）日：2002-12-26

  Method fore enhancing in a mammalian cell the activity of an enzyme associated with a lysosomal storage disorder by administering a competitive inhibitor of the enzyme in an amount effective to enhance the activity of the enzyme Prefcrred compounds for use in the method are imino sugars and related compounds

  通过给哺乳动物细胞添加酶的竞争性抑制剂来增强与溶酶体贮存障碍相关的酶的活性的方法，以有效增强酶的活性。在该方法中，优选用于使用的化合物是亚胺糖和相关化合物。
• Method for enhancing mutant enzyme activity in gaucher disease
  申请人：Mount Sinai School of Medicine

  公开号：US20030119874A1

  公开（公告）日：2003-06-26

  Method for enhancing in a mammalian cell the activity of an enzyme associated with Gaucher Disease by administering a competitive inhibitor of glucocerebrosidase in an amount effective to enhance the activity of the enzyme. Preferred compounds for use in the method are imino sugars and related compounds. In particular, C8-12-alkyl derivatives of N-alkyl-deoxynojirimycin, isofagomine compounds, and calystegine compoiunds are effective to enhance glucocerebrosidase activity.

  通过给哺乳动物细胞注射竞争性葡糖鞘氨酸酶抑制剂并使其剂量有效，以增强与高氏病相关的酶的活性的方法。该方法中用于的首选化合物是亚胺糖和相关化合物。特别是，N-烷基-脱氧诺吉霉素的C8-12-烷基衍生物、异法戈米素化合物和卡利斯特吉素化合物对于增强葡糖鞘氨酸酶的活性是有效的。
• Method for enhancing mutant enzyme activities in gaucher disease
  申请人：Fan Jian-Qiang

  公开号：US20050113415A1

  公开（公告）日：2005-05-26

  Method for enhancing in a mammalian cell the activity of an enzyme associated with Gaucher Disease by administering a competitive inhibitor of glucocerebrosidase in an amount effective to enhance the activity of the enzyme. Preferred compounds for use in the method are imino sugars and related compounds. In particular, C8-12-alkyl derivatives of N-alkyl-deoxynojirimycin, isofagomine compounds, and calystegine compounds are effective to enhance glucocerebrosidase activity.

  提高哺乳动物细胞中与戈谢病有关的酶的活性的方法，方法是施用有效量的葡萄糖脑苷脂酶竞争性抑制剂，以提高该酶的活性。用于该方法的优选化合物是亚氨基糖和相关化合物。特别是，N-烷基-脱氧野尻霉素的C8-12-烷基衍生物、异法戈明化合物和卡尔斯泰金化合物可有效增强葡萄糖脑苷脂酶的活性。